1 / 40

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136. Classes of recommendations. Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136. Levels of evidence.

reilly
Download Presentation

Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  2. Classes of recommendations Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  3. Levels of evidence Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  4. Investigational algorithm for patients with coronary artery disease and diabetes mellitus Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  5. Definition, classification, and screening of diabetes and pre-diabetic glucose abnormalities Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  6. Criteria used for glucometabolic classification according to the WHO (1999) and ADA (1997 and 2003) (values are expressed as venous plasma glucose) Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  7. Aetiological classification of glycaemia disordersaa Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  8. Conversion factors between plasma and other vehicles for glucose values Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  9. Fasting and post-load glucose levels identify different individuals with asymptomatic diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  10. FINnish Diabetes Risk SCore (FINDRISC) to assess the 10 year risk of type 2 diabetes in adults Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  11. Epidemiology of diabetes, IGH, and cardiovascular risk Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  12. Age- and gender-specific prevalence of diabetes in 13 European population-based cohorts included in the DECODE study Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  13. Identification of subjects at high risk for CVD or diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  14. Summary of the findings of four lifestyle intervention studies that aimed at preventing type 2 diabetes in subjects with IGT Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  15. Treatment to reduce cardiovascular riskLifestyle and comprehensive management Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  16. Mean efficacy of pharmacological treatment options in patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  17. Percentage of patients achieving pre-defined intensive treatment targets in the Steno 2 study Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  18. Glycaemic targets for the care of patients with diabetes as recommended by various organizations Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  19. Potential downsides of pharmacological treatment modalities in patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  20. Suggested policy for the selection of glucose-lowering therapy according to the glucometabolic situation Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  21. Treatment to reduce cardiovascular risk - Dyslipidaemia Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  22. Subgroups of patients with DM in the major secondary prevention trials with statins and the proportionate risk reduction in patients with and without diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  23. Treatment to reduce cardiovascular risk - Blood pressure Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  24. Treatment effects of antihypertensive drugs in comparison with placebo or less intensive treatment as reported in randomized clinical trials Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  25. Treatment effects expressed in hazard ratios (95% CI) in randomized clinical trials comparing different antihypertensive treatments in hypertensive patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  26. Management of CVD - Coronary artery disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  27. Treatment options based on accumulated evidence Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  28. Recommended treatment targets for patients with diabetes and CAD Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  29. Diabetes and coronary revascularization Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  30. Trials addressing diabetes and revascularization for multivessel disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  31. Revascularization in diabetes patients with multivessel disease in the stent-era Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  32. Heart failure and diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  33. Arrhythmias: atrial fibrillation and sudden cardiac death Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  34. Peripheral vascular disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  35. Investigations of the peripheral circulation in diabetic patients Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  36. Stroke Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  37. Intensive care Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  38. Published trials on intensive insulin therapy in critical illness Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  39. Health economics and diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

  40. Direct medical costs for patients with type 2 diabetes in eight European countries and percentage of healthcare expenditure in the respective countries (1998) Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136

More Related